Post-earnings recap
Reported
Wed, Nov 13, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
Est. EPS
—
Est. Rev
—
Impl. Move
—
IDEAYA Biosciences I's earnings report showed a significant stock price increase of 47.44%, indicating strong investor interest. The lack of revenue data and specific guidance suggests uncertainty, but the market reacted positively, likely due to the company's ongoing clinical initiatives. Investors may be optimistic about future developments despite the negative EPS.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.54 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management emphasized their commitment to ongoing clinical development. They did not provide specific guidance for the upcoming quarters.
Management did not provide specific guidance for future quarters.
The focus remains on advancing clinical programs and partnerships.